Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Docetaxel, Capecitabine, and Bevacizumab in Treating Patients With Metastatic Breast Cancer

This study has been completed.
Sponsor:
Collaborator:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00088998
First received: August 4, 2004
Last updated: December 23, 2010
Last verified: September 2005
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Estimated Study Completion Date: No date given
  Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Publications:
Perez EA, Hillman DW, Kugler JW, et al.: North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first line chemotherapy for patients with metastatic breast cancer. [Abstract] Breast Cancer Res Treat 100 (Suppl 1): A-2069, S104, 2006.